Integrated Multi-Modality Transfusion-Transmitted Disease (TTD) Testing Systems for Armed Services Blood Bank Center-Europe (ASBBC-EUR), Landstuhl Regional Medical Center (LRMC), Germany
The Defense Health Agency is conducting market research via an RFI to identify sources for a complete integrated multi-modality transfusion-transmitted disease testing solution for the Armed Services Blood Bank Center-Europe at Landstuhl Regional Medical Center, Germany, performed in a basement laboratory on a U.S. military installation under NATO SOFA. The requirement covers supply, installation, validation, training, ongoing maintenance, software support/upgrades, technical support, and reagents/consumables for three FDA CBER-cleared/licensed blood-donor screening platforms—immunohematology/ABO-Rh, syphilis, CMV, antibody titer; serology for HIV Ag/Ab, anti-HCV, HBsAg, HTLV I/II, anti-HBc, Chagas; and NAT for HIV, HBV, HCV, WNV, Babesia—at roughly 6,000 whole-blood units annually. Critical site constraints include about 585 usable square feet, single-phase 230 V/50 Hz power, treated/purified water, exact power/water/footprint data, and compatibility with the DoD/DHA LAN without commercial internet or vendor wireless networks. Both lease and purchase will be considered, with a preference for leased equipment, and respondents should address a potential relocation within 2–5 years to a new German facility not exceeding 50 km, with planning based on approximately 20 km. Interested parties should provide a capability statement of no more than 10 pages confirming FDA CBER status, single integrated or teaming approach, pricing constructs, in-country Germany/EU service capability, SAM registration with European/NATO CAGE code where applicable, and ability to meet a not-later-than operational date of 27 September 2027.